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Regulation of HIV-1 replication in human monocytes/macrophages occurs at multiple levels including transcription of the proviral genome,
which depends on virally encoded Tat protein. Interleukin-10 (IL-10), an anti-inflammatory cytokine which is up-regulated during disease
progression of AIDS, has been reported to suppress HIV-1 replication in macrophages at a post-entry stage of the virus life cycle. Our previous
studies have demonstrated that Tat function is regulated during the differentiation of monocyte-derived macrophages (MDMs) in a manner that
correlates with the early induction and subsequent shut-off of its cellular cofactor cyclin T1. Here, we report that IL-10 down-regulates cyclin T1
expression through the induction of proteasome-mediated proteolysis in human macrophages. Using a reporter virus that is deficient in Tat
function, we also demonstrate that IL-10 inhibits HIV-1 gene expression in a Tat-dependent manner. Together, these results suggest that the down-
regulation of cyclin T1, and consequently Tat function, contributes to the suppressive effect of IL-10 on HIV-1 replication in human macrophages.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV; Tat; IL-10; Cyclin T1; P-TEFb; Transcription; ProteolysisIntroduction
Cells from the monocyte/macrophage lineage are one of the
major targets for human immunodeficiency virus (HIV-1)
infection due to the expression of CD4 and CCR5 molecules
on their cell surface. Although infection appears to be generally
less productive than that in CD4+ T lymphocytes, monocytes
and macrophages are believed to make important contributions
to the transmission and pathogenesis of HIV-1 infection
throughout the course of disease progression (Verani et al.,
2005; Kedzierska and Crowe, 2002; Swingler et al., 1999),
especially at the late stages of acquired immunodeficiency
syndrome (AIDS) when CD4+ T lymphocytes have been
extensively depleted (Orenstein et al., 1997). Several different
steps of HIV-1 replication have been reported to be regulated in
monocytes/macrophages, including virus entry, nuclear import,
transcription of the provirus, and virus assembly/release (Verani
et al., 2005).⁎ Corresponding author. Fax: +1 713 798 3490.
E-mail address: arice@bcm.tmc.edu (A.P. Rice).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.05.013Efficient transcriptional elongation of the HIV-1 proviral
genome by cellular RNA polymerase II (RNAP II) requires the
virus-encoded transactivator protein known as Tat (Karn, 1999;
Garber and Jones, 1999; Rice and Herrmann, 2003; Barboric
and Peterlin, 2005). Tat activates transcription by recruiting a
cellular kinase complex composed of Cdk9 and cyclin T1 to the
TAR RNA stem-loop structure, located at the 5′ end of the
nascent RNA transcript. The Cdk9 and cyclin T1 complex is
one of the several kinase complexes expressed in human cells
that are collectively termed P-TEFb. Each P-TEFb complex
contains the catalytic subunit Cdk9, expressed as both a major
42-kDa and a minor 55-kDa isoform, plus a regulatory subunit,
either cyclin T1, cyclin T2, or cyclin K (Liu and Herrmann,
2005; Price, 2000; Shore et al., 2003). Tat binds directly to
cyclin T1 and therefore specifically recruits the cyclin T1-
containing P-TEFb complex. Upon the formation of the TAR-
Tat-P-TEFb ternary complex, transcriptional elongation is
activated by Cdk9 through hyperphosphorylation of the
carboxyl-terminal domain (CTD) of RNAP II and phosphory-
lation of negative factors that associate with RNAP II and limit
elongation (Price, 2000; Ivanov et al., 2000; Kim and Sharp,
2001; Garber and Jones, 1999; Fujinaga et al., 2004).
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levels of cyclin T1 protein are transiently induced by post-
transcriptional mechanisms during the differentiation of mono-
cytes toward macrophages in vitro (Liou et al., 2002). Freshly
isolated monocytes contain high levels of cyclin T1 mRNA but
express very low amount of cyclin T1 protein. During the first
few days of differentiation, cyclin T1 protein expression is up-
regulated without an increase in mRNA levels. After 7 to
10 days, however, cyclin T1 expression is shut-off by a post-
transcriptional mechanism involving proteasome-mediated
proteolysis (Liou et al., 2004). Plasmid transfection assays in
monocyte-derived macrophages (MDM) show parallel regula-
tion of Tat transactivation activity, suggesting that cyclin T1 is a
limiting factor for Tat function in MDMs (Liou et al., 2002).
Interestingly, HIV-1 infection has also been shown to prevent
the shut-off of cyclin T1 protein expression in macrophages
(Liou et al., 2004).
Cytokines and chemokines are host factors that continuously
regulate HIV-1 infection and replication in cells of the myeloid
lineage (Kedzierska et al., 2003). IL-10 is a potent immuno-Fig. 1. IL-10 inhibits cyclin T1 expression during MDM differentiation. (A) Flo
macrophages were stained with anti-CD14 or anti-CD71 antibodies (open area). Un
prepared at indicated time points were examined by SDS-PAGE followed with imm
Cells were lysed at 6, 14, and 24 h after the addition of IL-10 and were analyzed for ex
concentration of 10 ng/ml of IL-10 was used.suppressive cytokine which inhibits macrophage activation by
decreasing the production of pro-inflammatory cytokines such
as IL-6 and TNF-α (Moore et al., 2001). Elevated serum levels
of IL-10 and IL-4, concomitant with loss of IL-2 and IFN-γ
production, have been suggested to mark the progression to
AIDS (Clerici and Shearer, 1993). Since cells from the
monocytes/macrophages lineage play a pivotal role in HIV-1
persistence and pathogenesis, especially in AIDS patients
whose CD4+ lymphocytes have been extensively depleted
(Verani et al., 2005; Orenstein et al., 1997), it is important to
understand the interactions between IL-10 and the HIV-1
replication in the specific setting of monocytes/macrophages.
Previously, IL-10 has been reported to suppress HIV-1
replication in monocytes/macrophages at early stages of
infection, although virus entry does not appear to be affected
(Naif et al., 1996; Ancuta et al., 2001; Kootstra et al., 1994;
Wang et al., 1998). However, mechanisms of suppression by IL-
10 have not yet been elucidated.
In this study, we used primary human peripheral blood
MDMs to investigate the effects of IL-10 on cyclin T1w cytometric analysis of cell surface markers. Day 0 monocytes and day 4
stained cells were used as controls (shaded area). (B) 20 μg of total cell lysates
unoblot using the indicated antisera. β-Actin was used as a loading control. (C)
pression of the indicated proteins by immunoblotting. For all experiments, a final
Fig. 3. IL-10 down-regulates cyclin T1 expression in macrophages by inducing
proteasome-mediated proteolysis. The proteasome inhibitor MG101 (50 nM)
was added to IL-10-treated macrophages for 1 h before cells were lysed. 20 μg
of total lysates was separated by SDS-PAGE. Levels of indicated proteins were
examined by immunoblotting. Data from two independent experiments are
presented here.
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regulates cellular levels of cyclin T1 protein through the
induction of proteasome-mediated proteolysis. Furthermore, we
found that IL-10 suppresses HIV-1 gene expression in infected
MDMs by inhibiting Tat function.
Results
IL-10 represses cyclin T1 protein expression in differentiating
macrophages
To examine the effects of IL-10 on cyclin T1 expression,
MDMs were differentiated from monocytes using GM-CSF.
Flow cytometric analysis showed decreased expression of
monocytic marker CD14 and increased expression of
macrophage marker CD71 in cells that were not treated
with IL-10, indicating the expected differentiation of MDMs
(Fig. 1A). MDM cultures treated from day 2 of in vitro
differentiation with 10 ng/ml of IL-10 in addition to GM-CSF
demonstrated sustained expression of CD14 on day 4. The
induction of CD71 surface expression on these cells is similar
to that of the MDMs differentiated without IL-10, suggesting
that MDMs undergo similar maturation in the presence of IL-
10 (Fig. 1A). Interestingly, cyclin T1 protein expression was
greatly reduced after cells were differentiated in the presence
of IL-10 for 2 days (Fig. 1B, compare lanes 2 and 3), while
the expression of the 42-kDa isoform of Cdk9, which forms a
P-TEFb complex together with cyclin T1, was largely
unaffected at this time. To further characterize the kinetics
of this down-regulation, cell lysates were prepared at 6, 14, orFig. 2. IL-10 does not affect cyclin T1 RNA expression. Total RNAwas isolated
from macrophages treated with or without 10 ng/ml of IL-10 at the indicated time
points. RNAswere examined by real-timeRT-PCRas previously described (Haaland
et al., 2005) for the detection of cyclin T1 and CD11c cDNAs. Abundance of the
transcripts was normalized to that of GAPDH. Inhibition of cyclin T1 by IL-10 at the
protein level was confirmed by immunoblot (see Fig. 1B).24 h after the addition of IL-10 on day 2, and the expression
levels of cyclin T1 were examined by immunoblot (Fig. 1C).
Down-regulation of cyclin T1 was not observed at 6 h after
IL-10 addition. It became apparent by 14 h and by 24 h that
cyclin T1 was nearly undetectable. These results indicate that
the effect of IL-10 on cyclin T1 is a relatively slow process
and may be a late event induced by the cytokine. We
observed similar kinetics of cyclin T1 down-regulation by IL-
10 in MDMs from a number of other blood donors. We
therefore conclude that IL-10 down-regulates cyclin T1
expression in human macrophages by a relatively slow
process, which is likely to be a downstream effect of IL-10
binding to its receptor.
IL-10 does not affect cyclin T1 RNA expression
To explore the underlying mechanisms of cyclin T1 down-
regulation by IL-10, we examined cyclin T1 mRNA levels by
quantitative real-time RT-PCR (Fig. 2). As we previously
reported using cells differentiated with GM-CSF alone (Liou et
al., 2002), cyclin T1 mRNA levels are significantly higher in
monocytes than MDMs differentiated for 4 or 7 days. This
contrasts to the near absence of cyclin T1 protein expression in
day 0 monocytes, and the high-level protein expression in day 4
MDMs (Fig. 1B). Although IL-10 was able to dramatically
decrease the level of cyclin T1 protein in day 4 MDMs (Fig.
1B), the amount of cyclin T1 mRNA remained similar in
MDMs treated with and without IL-10 (Fig. 2). As a control to
validate our real-time RT-PCR assay, RNA levels of CD11c
were also examined. CD11c is an integrin whose protein
expression is known to be up-regulated through a transcriptional
mechanism (Noti and Reinemann, 1995). As expected, CD11c
mRNAwas strongly induced from day 0 to day 4 in cells treated
with GM-CSF alone, while the addition of IL-10 had only a
small negative effect on cyclin T1 mRNA on day 4. We
therefore conclude that the down-regulation of cyclin T1
expression by IL-10 is not the result of decreased levels of
cyclin T1 mRNA.
Fig. 4. IL-10 inhibits cyclin T1 protein expression in HIV-1-infected
macrophages. MDMs were infected on day 2 with NL4-3-Luc virus. 10 ng/ml
of IL-10 was added to culture on day 3. Cell lysates were prepared on indicated
time points and examined by immunoblot.
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Because MDMs differentiated with GM-CSF down-regulate
cyclin T1 expression at a late differentiation stage by a
proteasome-mediated process (Liou et al., 2002), we were
interested in examining whether IL-10 activates the same
process. We blocked proteasome-mediated proteolysis in IL-10-
treated macrophages with the proteasome inhibitor, MG101. As
shown in Fig. 3 for MDMs from 2 donors, treatment with
MG101 for 1 h prior to preparation of cell extracts was able to
overcome the suppressive effect of IL-10 on cyclin T1
expression. Treatment with MG101 had no significant effect
on the expression of CD11c, the 42-kDa Cdk9, or β-actin,
indicating the specificity of its effect on cyclin T1. These
results, together with our previous findings (Liou et al., 2002,
2004), indicate that the down-regulation of cyclin T1 protein in
differentiating macrophages is mediated by proteasome-medi-Fig. 5. IL-10 inhibits HIV-1 gene expression in macrophages by suppressing Tat fu
virus. Expression of wild-type Tat protein or mutant Tat-pro18IS was achieved by
prepared 48 h post-transfection and analyzed for luciferase activity. (B) Differentiatin
Luc-Tat− by spinoculation (O'Doherty et al., 2000b). IL-10 (10 ng/ml) was added in
Suppression of cyclin T1 expression in IL-10-treated macrophages was confirmed
described above.ated protein degradation. This process is accelerated by IL-10,
and it appears to be the major mechanism involved in the
inhibition of cyclin T1 expression by IL-10.
IL-10 inhibits cyclin T1 expression in HIV-1-infected
macrophages
Our previous studies have demonstrated induction of cyclin
T1 protein expression by HIV-1 infection (Liou et al., 2004). We
therefore examined whether this induction can be overridden by
the effect of IL-10. MDMs were infected on day 2 with NL4-3-
Luc, a reporter virus that encodes the full-length HIV-1 proviral
DNA and expresses luciferase enzyme in the place of Nef
(Connor et al., 1995). Consistent with our previous findings,
cyclin T1 protein expression was shut-off at day 5 in uninfected
cultures, whereas it was sustained in the infected culture that
was not treated with IL-10 (Fig. 4). In contrast, cyclin T1
expression was absent at both days 4 and 5 in infected cultures
that were treated with IL-10. These results indicate that under
these conditions, the repression of cyclin T1 expression by IL-
10 is dominant over the induction by HIV-1 infection.
Suppression of cyclin T1 expression by IL-10 contributes to its
inhibition on HIV-1 replication in human macrophages
Previous studies have indicated that IL-10 specifically inhibits
HIV-1 replication in primary human MDMs at a post-entry stage
(Ancuta et al., 2001; Kootstra et al., 1994;Wang et al., 1998; Naif et
al., 1996). We next examined whether the down-regulation of
cyclin T1 by IL-10 contributes to the inhibition ofHIV-1 replication
in MDMs. To investigate the impact of IL-10 on Tat-mediatednction. (A) 293T cells were infected with either NL4-3-Luc or NL4-3-Luc-Tat−
transfection (empty expression vector was used as a control). Cell lysates were
g MDMs were infected in triplicate on day 1 with either NL4-3-Luc or NL4-3-
to culture media on day 3. Cells were harvested every day beginning at day 5.
by immunoblotting (data not shown). Luciferase activities were examined as
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Luc-Tat− that lacks a functional Tat protein. This Tat mutant, Tat-
pro18IS, has been shown previously by plasmid transfection assays
to abolish Tat transactivation (Rice andCarlotti, 1990). In infections
using 293T cells, the wild-type reporter virus, NL4-3-Luc,
expresses efficiently, while mutation of Tat in the NL4-3-Luc-
Tat− virus reduced viral expression by ∼32-fold (Fig. 5A).
Luciferase expression of the NL4-3-Luc-Tat− virus could be
restored to a similar level as that of the wild-type virus by
cotransfecting a plasmid expressing the wild-type Tat but not a
plasmid expressing the mutant Tat-pro18IS. These results indicate
that NL4-3-Luc-Tat− is defective in Tat function, yet it can be fully
complemented by exogenously expressing wild-type Tat. We then
tested the effects of IL-10 on MDMs infected with these two
viruses. MDMs were infected with either NL4-3-Luc or NL4-3-
Luc-Tat− on day 1 and treated with IL-10 on day 3. From day 5 to
day 7, luciferase expression inNL4-3-Luc-infectedMDMswas less
in IL-10-treated cells than that in untreated cells (Fig. 5B). In
contrast, luciferase activities in MDMs infected with the mutant
virus, NL4-3-Luc-Tat-, were similar in cells treated with or without
IL-10, although the overall expression level in the Tat− virus-
infected cells was ∼30-fold lower than the wild-type virus due to
the absence of Tat transactivation (Fig. 5B). We observed similar
results in infectionswith these viruses inMDMs from several blood
donors. These results indicate that the inhibition of Tat transactiva-
tion by IL-10 contributes to the suppression of HIV-1 gene
expression by this cytokine.
Discussion
Despite thewell-documented anti-inflammatory functions of IL-
10, the mechanisms through which IL-10 suppresses macrophage
activation are diverse and poorly understood. Phosphorylation and
activation of the Jak/Stat pathway are thus far the best-characterized
signaling event triggered by IL-10 in macrophages. However,
previous studies indicate that one ormore additional pathwaysmust
also be activated to achieve the inhibitory effect of IL-10 on
macrophage activation (Moore et al., 2001). The results presented
here show that the IL-10 is able to down-regulate the expression of
cyclin T1, a major component of the P-TEFb transcription
elongation complex in human MDMs. The suppression of cyclin
T1 by IL-10 appears to be due to the induction of proteasome-
mediated proteolysis, which, to our knowledge, is a novel
observation on cellular events triggered by IL-10. It is not clear,
however, what signal(s) causes the induction of degradation in
MDMs differentiated with GM-CSF in the absence of IL-10. We
believe that it is unlikely that the accumulation of IL-10 in the
culturemedium triggers this event, aswe have been unable to detect
any activity in the conditioned culture medium from day 7MDMs,
where cyclin T1 had been expressed at low levels, which
accelerated the down-regulation of cyclin T1 in early MDM
cultures (unpublished results).We also attempted to block the effect
of IL-10 by neutralizing it with monoclonal antibodies. We were
able to block the down-regulation of cyclin T1 by mixing
exogenous IL-10 with antibodies before cytokine addition to
cells. However,we have been unable to observe any effect on cyclin
T1 expression after the addition of antibodies against anyendogenous IL-10 which may be secreted into culture media
during macrophage differentiation (unpublished data). If IL-10 is
involved in the natural shut-off of cyclin T1 expression that occurs
late in differentiation in vitro, it is possible that its effect is carried
out through autocrine functions rather than paracrine signaling.
Proteasome-mediated protein degradation has been identi-
fied as a regulatory mechanism for many cellular processes
(Pickart, 2004; Ciechanover, 1994). Proteins that undergo rapid
turnover usually contain sequence identifiers for targeted
degradation, such as PEST regions, KEFRQ motifs and cyclin
destruction boxes (Rechsteiner and Rogers, 1996). Cyclin T1
contains a putative PEST sequence in its carboxyl terminus (Wei
et al., 1998), which may specify cyclin T1 degradation by the
ubiquitylation and proteasome pathway. Alternatively, it is
possible that an unidentified cellular factor is required for the
translation of cyclin T1 mRNA, and this positive factor may be
down-regulated through IL-10-induced proteolysis; blockage of
proteasome-mediated proteolysis by MG101 may increase the
level of this putative positive factor, and this would result in
increased translation of cyclin T1 mRNA and a subsequent
increase in the level of cyclin T1 protein. Our data cannot
distinguish these possibilities, although we favor the former
because it is commonly involved in regulating levels of cellular
transcription factors and cyclin-cdk complexes (Obaya and
Sedivy, 2002; Muratani and Tansey, 2003). Interestingly,
suppressing cyclin T1 expression through proteasome-mediated
degradation appears to be specific for macrophages as treatment
of peripheral blood lymphocytes, Jurkat, and 293T cells with
proteasome inhibitors does not affect its protein level (Liou et
al., 2004). Transcription profiling studies in control MDMs and
MDMs treated with IL-10 are currently underway in an attempt
to identify enzymes and accessory proteins induced by IL-10
that may be involved in the down-regulation of cyclin T1.
To date, reports on the impact of IL-10 on HIV-1 replication
in monocytes/macrophages have been divergent and dependent
on the cell types and amounts of cytokine used in the
experiments (Stearns et al., 2003; Sozzani et al., 1998; Ancuta
et al., 2001; Kootstra et al., 1994; Naif et al., 1996; Wang et al.,
1998). Our data are also consistent with the findings that IL-10,
by itself, affects HIV-1 replication negatively in macrophages.
In conclusion, our results demonstrate that IL-10 down-
regulates the expression of cyclin T1, probably though the
activation of proteasome-mediated proteolysis of this protein.
We also present evidence that the inhibition of HIV-1 replication
in MDMs by IL-10 involves the suppression of Tat transactiva-
tion function during the transcription of HIV-1 provirus. Our
findings, together with other reports (Moore et al., 2001),
suggest that IL-10 may affect multiple stages of the HIV-1 life
cycle, and its induced expression in progressive AIDS patients
may have a complex effect on HIV-1 pathogenesis.
Materials and methods
Reagents and antibodies
Human granulocyte–macrophage colony-stimulating factor
(GM-CSF) and interleukin-10 (IL-10) were purchased from R&D
490 Y. Wang, A.P. Rice / Virology 352 (2006) 485–492Systems. Anti-CD14-PE and anti-CD71-FITC were from BD
PharMingen. Primary antibodies against cyclin T1 (T-18), Cdk9
(C-20) and CD11c (C-20) were purchased from Santa Cruz
Biotechnology.Anti-β-actin antibody andMG101were fromSigma.
Isolation and differentiation of monocytes/macrophages
Peripheral blood mononuclear cells (PBMCs) were isolated
from the buffy coat of healthy blood donors (Gulf Coast
Regional Blood Center) by Ficoll-Hypaque density gradient
centrifugation (Isolymph [Gallard/Schlesinger]). Monocytes
were isolated by an adherence method in which 3 × 107
PBMCs were seeded onto each 10-cm plastic tissue culture dish
(Sarstedt) containing RPMI-1640 (Invitrogen) supplemented
with 1% human serum (Sigma) and 1% antibiotics (Invitrogen).
Following incubation at 37 °C for 1 h, non-adherent cells were
removed, and adherent monocytes were washed vigorously
with pre-warmed phosphate-buffered saline (PBS). Cells were
further purified by incubating at 37 °C for 2 h in complete
medium (RPMI-1640 + 10% fetal bovine serum + antibiotics)
and washing with pre-warmed PBS vigorously for 3 times.
Monocytes were then cultured in complete medium containing
10 U/ml GM-CSF to allow differentiation into macrophages.
For IL-10 treatment, a one-time addition of IL-10 was
introduced on day 2 to a final concentration of 10 ng/ml. Initial
seeding conditions for other formats of tissue culture vessels are
2 × 106 PBMCs per 6-cm dish or 1 × 106 PBMCs per well in a
6-well plate. In some experiments, monocytes were also
isolated from PBMCs using the negative selection-based
Monocyte Isolation Kit II (Miltenyi Biotech.) to achieve a
purity of 90% or higher as determined by flow cytometry.
Flow cytometry
Adherent cells were collected by incubating the dishes at
4 °C with PBS containing 2% FBS and 2 mM EDTA for 10 min
and detaching the cells using a rubber scraper. Cells were
washed twice with cold PBS containing 2% FBS and stained for
15 min at 4 °C with appropriate antibodies. After washing, cells
were fixed in 1% paraformaldehyde (Fisher) and analyzed using
a Coulter XL-MCL flow cytometer.
Immunoblots
Cell lysates were prepared using Luciferase Cell Lysis Buffer
(Promega) according to the manufacturer's protocol. Protein
concentration was determined by a Bradford assay (Bio-Rad).
20 μg of total lysate was separated by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). The procedure for
immunoblotting using SuperSignal West Pico Chemiluminescent
Substrate (Pierce) was described previously (Herrmann et al., 1996).
Isolation of total RNA and analysis by quantitative real-time
RT-PCR
Total RNA was extracted from frozen cell pellets using the
RNeasy mini kit (Qiagen). RNA concentration was determinedby measuring OD260 nm of the sample. 1 μg of the total RNA
was reverse transcribed using iScript cDNA synthesis kit (Bio-
Rad) in a 20 μl reaction according to the manufacturer's
protocol. Products from these reactions were diluted 1:10 and
used as templates in 15 μl real-time PCR reactions containing 1/
2 volume of 2× iQ SYBR Green Supermix (Bio-Rad) and
200 nM final concentration of the appropriate primers.
Triplicate PCR reactions were run in 96-well format using a
Bio-Rad iCycler. After the initial hot start at 95 °C for 3 min, 40
cycles of amplification were carried out for 15 s at 95 °C
followed by 1-min annealing/extension at 55 °C (data were
collected at this step). Analysis was performed using the MyIQ
software program (Bio-Rad), which automatically determines
the threshold crossing (CT) value for each reaction. A five-fold
dilution series of HeLa cell total RNAwas used to determine the
amplification efficiency (E) of each primer pair. The relative
expression ratio (R) of a gene of interest (g.o.i., normalized to
day 0) was calculated with the following formula using GAPDH
as a reference gene (Pfaffl, 2001).
R ¼ 1þ Eg:o:i:
 DCTg:o:i:ðday 0sampleÞ
1þ Erefð ÞDCTrefðday 0sampleÞ
Sequences of the primers used here are as follows: cyclin T1
(sense 5′-AACCTTCGCCGCTGCCTTC-3′; anti-sense 5′-
ACC GTTTGTTGTTGTTCTTCCTCTC-3′), CD11c (sense
5′-TTTGAGTGTCGGGAGCAGGTG-3′; anti-sense 5′-
GCCAGGTCCAAGGTCACAGAG-3′), GAPDH (sense 5′-
CGCCAGCCGAGCCACATC-3′; anti-sense 5′-AATCCCTT-
GACTCCGACCTTCA-3′).
Virus production and infections
pNL-Luc-E−R+ was obtained from the NIH AIDS Research
and Reference Reagent Program and has been described
previously (Connor et al., 1995). pNL-Luc-E−R+ encodes for
full-length NL4-3 HIV-1 proviral DNAwith a frameshift in Env
and expresses luciferase enzyme in place of Nef. To generate the
Tat-null virus, NL4-3-LucTat−, an EcoRI restriction endonu-
clease site (GAATTC) was inserted between residues 18 and 19
within the Tat-encoding sequence of pNL-Luc-E−R+ using
QuickChange II XL site-directed mutagenesis kit (Stratagene).
For virus production, 5 × 106 293T cells were transfected with
10 μg of either pNL-Luc-E-R+ or pNL-Luc-E−R+Tat−, along
with 10 μg of plasmids expressing VSV-G protein (pseudotyped
envelope) and HIV-1 Tat protein by calcium phosphate
transfection (Sambrook and Russell, 2001). Culture supernatant
containing infectious virions was harvested 72 h post-
transfection and cleared of cell debris by centrifuging at
1000×g for 10 min. Virus concentration was determined by the
COULTER HIV-1 p24 antigen assay using protocols supplied
by the manufacturer. Virus stock was stored at −80 °C in
working aliquots. For infection of 293T cells, 3 × 105 293T cells
(ATCC) in 12-well plates were infected in triplicate with 5 μg of
either NL4-3-Luc or NL4-3-Luc-Tat−. Infection of primary
human MDMs was carried out in 6-well plates using 50 μg/ml
of either virus. The method of spinoculation was employed to
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et al., 2000a), cells were incubated with virus-containing media
under 2000×g of centrifugational force for 2 h. Unbound virus
was removed by washing the cells 3 times with cold PBS.
Complete media containing 10 U/ml GM-CSF were added to
the cells for further culturing.
Transfections and luciferase assay
Transient transfection was carried out using Lipofectamine
2000 transfection reagent (Invitrogen). 3 × 105 293T cells,
infected with either NL4-3-Luc or NL4-3-Luc-Tat−, were
transfected in triplicates with 0.5 μg of either the control
vector, Tat-expressing or Tat mutant-expressing plasmid. Cells
were harvested 48 h later. Luciferase activity in cell lysates was
detected using the Luciferase Assay System from Promega
according to protocols supplied therein.
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